[go: up one dir, main page]

EA200701894A1 - LEVEL OF TRANSCRIPTION OF THE TIMP3 GENE AS A DIAGNOSTIC MARKER FOR NON-SMALL-CELL LUNG CANCER - Google Patents

LEVEL OF TRANSCRIPTION OF THE TIMP3 GENE AS A DIAGNOSTIC MARKER FOR NON-SMALL-CELL LUNG CANCER

Info

Publication number
EA200701894A1
EA200701894A1 EA200701894A EA200701894A EA200701894A1 EA 200701894 A1 EA200701894 A1 EA 200701894A1 EA 200701894 A EA200701894 A EA 200701894A EA 200701894 A EA200701894 A EA 200701894A EA 200701894 A1 EA200701894 A1 EA 200701894A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lung cancer
cell lung
level
transcription
small
Prior art date
Application number
EA200701894A
Other languages
Russian (ru)
Other versions
EA010571B1 (en
Inventor
Тамара Дмитриевна Машкова
Нина Юрьевна Опарина
Ольга Леонидовна Зиновьева
Евгений Павлович КОПАНЦЕВ
Татьяна Викторовна ВИНОГРАДОВА
Марина Валерьевна ЗИНОВЬЕВА
Ирина Борисовна Зборовская
Original Assignee
Институт Молекулярной Генетики Российской Академии Наук (Имг Ран)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) filed Critical Институт Молекулярной Генетики Российской Академии Наук (Имг Ран)
Publication of EA200701894A1 publication Critical patent/EA200701894A1/en
Publication of EA010571B1 publication Critical patent/EA010571B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Настоящее изобретение относится к области медицины, в частности онкологии, и молекулярной биологии. Предложено в качестве маркера для диагностики немелкоклеточного рака легких использовать уровень транскрипции гена TIMP3. Сниженный уровень транскрипции в предположительно пораженной раком ткани человека по сравнению с ее уровнем в здоровой ткани служит диагностическим признаком немелкоклеточного рака легких. Предложенное изобретение позволяет с высокой достоверностью диагностировать немелкоклеточный рак легких, включая плоскоклеточный рак, в том числе на самой ранней стадии прогрессии опухолевой трансформации.The present invention relates to the field of medicine, in particular oncology, and molecular biology. It is proposed to use the transcription level of the TIMP3 gene as a marker for the diagnosis of non-small cell lung cancer. The reduced level of transcription in supposedly diseased human tissue compared with its level in healthy tissue serves as a diagnostic sign of non-small cell lung cancer. The proposed invention allows with a high certainty to diagnose non-small cell lung cancer, including squamous cell cancer, including at the earliest stage of the progression of tumor transformation.

EA200701894A 2006-08-15 2006-08-15 Method for diagnosis of non-small cell carcinoma of lung and a kit therefor EA010571B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2006/000430 WO2008024009A1 (en) 2006-08-15 2006-08-15 Transcriptional level of a timp3 gene in the form of a diagnosis marker of a non-small cell carcinoma of lung

Publications (2)

Publication Number Publication Date
EA200701894A1 true EA200701894A1 (en) 2008-02-28
EA010571B1 EA010571B1 (en) 2008-10-30

Family

ID=39107023

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701894A EA010571B1 (en) 2006-08-15 2006-08-15 Method for diagnosis of non-small cell carcinoma of lung and a kit therefor

Country Status (2)

Country Link
EA (1) EA010571B1 (en)
WO (1) WO2008024009A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
CN107771221B (en) 2015-02-10 2021-11-02 香港中文大学 Mutation Detection for Cancer Screening and Fetal Analysis
ES2960201T3 (en) 2015-07-23 2024-03-01 Univ Hong Kong Chinese Analysis of acellular DNA fragmentation patterns
DK3574108T3 (en) 2017-01-25 2024-09-16 Univ Hong Kong Chinese DIAGNOSTIC USE USING NUCLEIC ACID FRAGMENTS
AU2018305609B2 (en) 2017-07-26 2023-01-19 The Chinese University Of Hong Kong Enhancement of cancer screening using cell-free viral nucleic acids

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001264559A1 (en) * 2000-06-05 2001-12-17 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
DE10161625A1 (en) * 2001-12-14 2003-07-10 Epigenomics Ag Methods and nucleic acids for the analysis of a pulmonary cell division disorder

Also Published As

Publication number Publication date
EA010571B1 (en) 2008-10-30
WO2008024009A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
WO2013182912A3 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
WO2012103250A3 (en) Colon cancer gene expression signatures and methods of use
WO2010017515A3 (en) Breast cancer specific markers and methods of use
EP3208615A3 (en) Uses of labeled hsp90 inhibitors
WO2012068383A3 (en) ncRNA AND USES THEREOF
WO2010081001A3 (en) Recurrent gene fusions in cancer
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
EP2706068A3 (en) Identification of tumor-associated markers for diagnosis and therapy
WO2010091049A3 (en) Diagnosis and treatment of cancer
HK1213946A1 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
EP2198021A4 (en) Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
WO2011028698A3 (en) Mri and optical assays for proteases
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2011034906A3 (en) Recurrent gene fusions in prostate cancer
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
IL201778A0 (en) Peptide imaging agents
WO2012129488A3 (en) Gene signatures associated with rejection or recurrence of cancer
WO2008003656A3 (en) Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
EA201690004A1 (en) ANTIBODIES AGAINST LAMP1 AND CONJUGATES ANTIBODIES AND MEDICINES AND THEIR APPLICATION
BR112013016107A2 (en) dimeric molecule, cancer treatment method, pharmaceutical composition and kit for the diagnosis of an upar-mediated pathology or tumor
EA200701894A1 (en) LEVEL OF TRANSCRIPTION OF THE TIMP3 GENE AS A DIAGNOSTIC MARKER FOR NON-SMALL-CELL LUNG CANCER
WO2007002746A3 (en) Molecular/genetic aberrations in surgical margins of resected pancreatic cancer represents neoplastic disease that correlates with disease outcome
EA201290107A1 (en) METHOD FOR DETERMINING A PATIENT AS A SUSTAINABLE OR NOT SUSTAINABLE FOR IMMUNOTHERAPY
ATE545867T1 (en) I-PLASTIN TEST METHOD FOR IN VITRO DIAGNOSIS OF COLORECTAL CARCINOMA
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU